


Discover the volumizer
designed to stimulate collagen
with results that last over 2 years*


Elaine: Age 40 (2.5 vials)



Christine: Age 39 (2 vials)



Veronica: Age 33 (4 vials)



sculptra[®] aesthetic
injectable poly-L-lactic acid

stimulates collagen for a natural look


Actual *Sculptra Aesthetic* patients at 12 months

*Clinical trial ended at 25 months

Sculptra® Aesthetic is designed to stimulate collagen naturally

The Underlying Causes Of Facial Aging¹⁻⁶


Collagen loss along with other subdermal processes of fat loss and fat pad migration is a key factor in the aging process



As skin ages, the middle layer of skin (dermis) thins due to collagen loss, reducing the skin's ability to retain elasticity (from elastin) and moisture (from hyaluronic acid).

Loss of elastin and hyaluronic acid results in skin that is:


- drier
- less supple
- less elastic
- thinner due to volume loss



Loss of volume in the subdermal tissues starts early in life and progresses, manifesting in these visible signs of aging including:

- wrinkles
- folds
- lines

66% of new collagen growth seen at 3 months above baseline



In an exploratory study Sculptra® Aesthetic significantly grew collagen^{7*}

In an exploratory single-arm, open-label study titled *A Single-Arm Study for the Characterization of Human Tissue Response to Injectable Poly-L-lactic Acid*, 14 healthy subjects were administered injectable PLLA; punch biopsies at 3, 6 and 12 months were analyzed for qualitative and quantitative changes from baseline in collagen types I and III, and assessed for inflammatory response. Post hoc assessments at 12 months showed nominal collagen increases, (not statistically significant) but were hindered by technical difficulties. Results of this study in humans found statistically significant stimulation of collagen type I with no mild inflammatory response following administration of injectable PLLA.

In a separate study, nasolabial biopsies from a 55-year-old woman, 12 and 30 months after last treatment with Sculptra Aesthetic (injectable poly-L-lactic Acid).⁸




Figure 1: 12 Months

Figure 2: 30 Months

Figure 1. Histologic examination (original magnification x 400) exhibiting microparticles of PLLA at 12 months after last treatment, with adjacent aggregation of giant cells, histiocytes and collagen fibers.

Figure 2. Histologic examination (original magnification x 400) of the injected PLLA at 30 months after last treatment, showing the lack of PLLA microparticles and the abundance of collagen fibers.


A = Collagen Type 1
B = Sculptra Aesthetic

Provides natural-looking results that last over 2 years**

**Clinical trial ended at 25 months.

Sculptra® Aesthetic gradually volumizes, providing optimal and natural correction

- Sculptra Aesthetic (n=116)
- CosmoPlast® collagen (n=117)




P<0.001 from baseline for all Sculptra Aesthetic follow-up timepoints.

WAS: 0=no wrinkles; 1=just perceptible wrinkles; 2=shallow wrinkles; 3=moderately deep wrinkles; 4=deep wrinkles; 5=very deep wrinkles, redundant fold. CosmoPlast (human-derived collagen) is a registered trademark of Allergan, Inc.

Randomized, evaluator-blinded, parallel-group, multicenter study of 233 patients. The treatment phase consisted of 1 to 4 visits at 3-week intervals during which patients received bilateral injections (average of all injections was 2.3 vials) of Sculptra Aesthetic (n=116) or collagen (n=117) into the left and right nasolabial fold wrinkles. The follow-up phase consisted of visits at week 3 and months 3, 6, 9, and 13 after the last treatment. Of the 116 patients treated with Sculptra Aesthetic, 106 patients completed the study and continued into the long-term surveillance phase, which extended to 25 months.^{7,10}

86.3% of patients still showed overall improvement at 25 months after treatment, as rated by investigators^{7*}




*Investigators used a 5-point scale (4=excellent improvement, 3=much improved, 2=improved, 1=no change, 0=worse) for global evaluations.⁷
 †Randomized, evaluator-blinded, parallel-group, multicenter study of 233 patients.

High levels of patient satisfaction

80.0% of patients still rated their results as “good to excellent” at 25 months^{7*†}

*Randomized, evaluator-blinded, parallel-group, multicenter study of 233 patients.⁸

†Based upon good, very good, and excellent scores.



Sculptra® Aesthetic stimulates natural


collagen
to provide facial volume

Vivian: 53 Years Old (4 vials) 12 months



Individual results may vary

Individual results and treatment regimens may vary (all photos unretouched)



Left Cheek:
Volume change +7.065 cc

Right Cheek:
Volume change +8.323 cc

This image is an overlay of a baseline and 12 month post treatment 3D model. The space between the model illustrates the increase in volume. 3D images were captured using a VECTRA® imaging system (Canfield Imaging Systems, Fairfield NJ)


Sculptra[®] Aesthetic allows you to create a natural

Individual results and treatment regimens may vary (all photos unretouched)

JB: 40 Years Old (4 vials) 5 months



Franca: 42 Years Old (5 vials) 25 months



Individual results may vary

Elissa: 49 Years Old (5 vials) 25 months



Individual results may vary

7 months

Pam: 63 Years Old (6 vials) 9 months



Individual results may vary

look

that lasts for more than 2 years

Individual results and treatment regimens may vary (all photos unretouched)

Terry: 57 Years Old (7 vials) 9 months



Lisa: 50 Years Old (1 vial) 1 month



Individual results may vary

sculptra® aesthetic | stimulates collagen for a natural look
injectable poly-L-lactic acid

Precise and Predictable Use

Unlike most traditional fillers, with *Sculptra*® Aesthetic a reflux maneuver can be performed to avoid intravascular injection. If no blood is pulled back into the syringe, you may easily continue the threading or tunneling technique.¹⁰

Safety results in a key clinical trial (physician-reported events)

- Occurrence of physician-reported papules^{10**}
 - 8.6% at 13 months; 1.9% at 25 months
- Occurrence of physician-reported nodules^{10**}
 - 8.6% at 13 months; 0.9% at 25 months
- Occurrence of injection site pain recalled from patient diaries^{10*}
 - 9.5% at 13 months; 0.9% at 25 months
- Papules and nodules were typically palpable, asymptomatic, and non-visible¹⁰
- The majority of nodule and papule events were mild to moderate and 95% resolved without treatment¹⁰
- Injection site granulomas were not observed in clinical trials, but have been received from post-marketing surveillance in the US and outside¹⁰

*Patients experiencing multiple episodes of a given adverse event were counted once within each Medical Dictionary for Regulatory Activities term.¹⁰ †Nodules were defined as lesions > 5 mm; papules were defined as lesions < 5 mm.⁷

Indication and Important Safety Information

Indication: *Sculptra* is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging.

Sculptra is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).

Important Safety Information: Immediately following an injection session with *Sculptra*, redness, swelling and/or bruising may occur at the injection site. These typically resolve in hours to one week after the injection.

Hematoma (blood spot under the skin) may also occur, typically resolving in hours to about two weeks.

Treatment with *Sculptra* can also result in small papules in the treatment area. These subcutaneous (beneath the skin) papules are typically not visible and asymptomatic, and may be noticed only upon pressing on the treatment area.

Visible nodules, sometimes with redness or colour change to the skin, have also been reported.

Long-term safety and effectiveness of *Sculptra* beyond two years have not been studied in controlled clinical trials.

Minimize exposure of the treatment area to excessive sun and avoid UV lamp exposure until any initial swelling and redness have resolved. If laser treatment, chemical peeling or any other procedure based on active dermal response is considered after treatment with *Sculptra*, there is a possible risk of eliciting an inflammatory reaction at the implant site. This also applies if *Sculptra* is administered before the skin has healed completely after such a procedure.

No studies of interactions of *Sculptra* with drugs or other substances or implants have been made.

The safety of using *Sculptra* in patients with susceptibility to keloid formation and hypertrophic scarring has not been established. *Sculptra* should not be used in patients with known history of or susceptibility to keloid formation or hypertrophic scarring.

As with all transcutaneous procedures, *Sculptra* injection carries a risk of infection. Standard precautions associated with injectable materials should be followed.

As with all injections, patients treated with anticoagulants may run the risk of a hematoma or localized bleeding at the injection site.

The safety of *Sculptra* for use during pregnancy, in breastfeeding females or in patients under 18 years has not been established.

References: 1. Sharma, S.R. Effect of vitamin C on collagen biosynthesis and degree of birefringence in polarization sensitive optical coherence tomography (PS-OCT). *African Journal of Biotechnology* Vol. 7 (12), pp. June.2008;2049-2054. 2. Wiest, Luitgard. Native hyaluronic acid in dermatology. *JDDG* 2008; 176-180 3. Roberts, Wendy E. Dermatologic Problems of Older Women. *Dermatol Clin* 24. April.2006; 271-280. 4. Datta, Hema Sharma. Theories and Management of Aging: Modern and Ayurveda Perspectives. eCAM. January.2009;1-6. 5. Zimble, Marc S. Anatomy and Pathophysiology of Facial Aging. *Facial Plast Surg Clinics of North America* Vol 9. May.2001;179-187. 6. Variani, James. Decreased Collagen Production in Chronologically Aged Skin. *American Journal of Pathology*, Vol. 168, No. 6, June.2006; 1861-1868. 7. Data on file, Valeant Pharmaceuticals North America LLC. 8. Vleggaar, Danny. Facial Enhancement and the European experience with Sculptra. *et al Journal of Drugs in Dermatol.* 2004;3-542-547 9. Narins, Rhoda S. A randomized study of the efficacy and safety of injectable poly-L-lactic acid vs. human based collagen implant in the treatment of nasolabial fold wrinkles. *JAAD.* March.2010;448-462. 10. *Sculptra*® Aesthetic Prescribing Information; 2012.

Before and After Photos courtesy of Burke Robinson MD, J. Todd Andrews MD, Theresa Jarmuz MD